5 Key Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE: JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos. However, the stock market rewards investors based on future expectations, not past successes. If J&J is going to keep putting up impressive results, it's going to need to keep cashing in on its fastest-growing medicines.
Johnson & Johnson markets top consumer-goods brands like Band-Aid, and it's a big player in medical devices. But make no mistake -- this company's success or failure depends heavily on the performance of its pharmaceuticals business.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Aktie
148,28 €
-0,34 %
Johnson & Johnson erfreut sich großer Beliebtheit, mit einer hohen Zahl an Buy- und niedriger Zahl an Sell-Einschätzungen.
Das Kursziel von 194 € für Johnson & Johnson impliziert eine deutliche Steigerung um über 20% gegenüber 148.28 €.
